Milestone Pharmaceuticals (MIST) earnings call transcripts

Management framed the launch as gaining traction, with broader coverage enabling patient activation and a shift toward deeper prescribing alongside continued prescriber growth.

Management framed the call around an early but encouraging launch, an ahead-of-plan payer win, and initiation of AFib RVR development.

Management framed 2025 as a transition from FDA approval to launch execution, with early access encouraging but too immature to establish durable demand or trends.